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Abstract
Background: The prevalence of smoking in patients with schizophrenia is higher than that in the general
population and is an important medical issue. Short-term smoking cessation tends to worsen psychiatric symptoms
in patients with schizophrenia but decreases sympathetic nervous system activity and improves plasma cholesterol
levels in healthy people. Few studies have assessed the long-term effects of smoking cessation in patients with
schizophrenia.
Methods: Subjects were 70 Japanese patients with schizophrenia (38 smokers, 32 non-smokers). We compared the
following clinical parameters between the two groups at baseline (before smoking cessation) and in each group
separately between baseline and at three years after smoking cessation: autonomic nervous system activity, plasma
cholesterol levels, body weight, drug therapy, and Global Assessment of Functioning scores. We also compared the
mean changes in clinical parameters throughout this study between the groups at both time points. Autonomic
nervous system activity was assessed by power spectral analysis of heart rate variability.
Results: Parasympathetic nervous system activity and the doses of antiparkinsonian drugs in smokers were
significantly higher than those in non-smokers at baseline. Smoking cessation was associated with significantly
decreased sympathetic nervous system activity and decreased doses of antipsychotics and antiparkinsonian drugs
at three years after smoking cessation. However, there was no significant difference in the mean change in clinical
factors scores, except for Global Assessment of Functioning scores, between smokers and non-smokers at three
years after smoking cessation.
Conclusions: Our results suggest that smoking reduces both autonomic nervous system activity and the
effectiveness of drug therapy with antipsychotics and antiparkinsonian drugs in patients with schizophrenia, but
that both factors could be ameliorated over the long term by smoking cessation. Taken together with the findings
of previous studies, smoking cessation in patients with schizophrenia has many long-term positive physiological
effects.
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Background
The prevalence of smoking in patients with schizophrenia
is at least two to three times higher than that in the gen-
eral population [1–3]. Patients with schizophrenia experi-
ence greater difficulties in smoking cessation compared
with the general population [1–3]. Given the problems as-
sociated with smoking, this habit among patients with
schizophrenia is of clinical significance. Smoking cessation
has various positive physiological effects in healthy people,
including lower serum cholesterol levels and decreased
sympathetic nervous system activity [4–9]; increased sym-
pathetic nervous activity increases the risk of cardiac
disease, such as atrial and ventricular arrhythmias, cardiac
arrest, and acute myocardial infarction [10–13]. However,
as a negative physiological effect, a previous study
reported that smoking cessation for one year resulted in
weight gain [14].
Several studies have investigated the effects of smoking
and smoking cessation in patients with schizophrenia.
One study showed an association between smoking and
high serum lipid profiles [15], and another found that
smoking cessation for one year was associated with
worsening of Global Assessment of Functioning (GAF)
scores [16]. However, few studies have assessed the long-
term effects of smoking cessation in these patients. The
present study aimed to address this gap by investigating
the long-term effects of smoking cessation in patients
with schizophrenia, such as the effects on serum choles-
terol levels, body weight, drug therapy, GAF scores, and
autonomic nervous system (ANS) activity.
Methods
Subjects
This study involved 38 smokers (7 men, 31 women; 57.9
± 12.5 years) and 32 non-smokers (11 men, 21 women;
54.3 ± 13.6 years) with schizophrenia diagnosed according
to the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition (DSM-IV), by a psychiatrist. They
were all inpatients at a psychiatric hospital during the
study period. Exclusion criteria were (1) onset of chronic
medical conditions (e.g., diabetes, respiratory disease, car-
diac disease, or ANS disorders) at any point during the
study and (2) cardiovascular disease, arrhythmia, and long
QT syndrome as determined in all patients by chest radi-
ography and electrocardiography. Regular blood tests,
chest radiography and electrocardiography were per-
formed once a year and subjects were evaluated by a
psychiatrist regularly throughout the study period. All 38
smokers were habitual smokers, with a Tobacco Depend-
ence Screener (TDS) score of > 5 points (mean score 5.71
± 0.65). The TDS is a self-administered questionnaire for
assessing nicotine dependence as defined by the 10th
revision of the International Statistical Classification of
Diseases and Related Health Problems and DSM-IV [17],
the cutoff score for TDS is 5 points for diagnosis accord-
ing to ICD-10 [17]. The 32 non-smokers had never
smoked before. Based on the stipulation of the hospital’s
own smoke-free policy instituted in 2010, the 38 smokers
quit smoking. After instituting the policy, we assessed the
subjects over the subsequent three-year period. None of
the 38 smokers received any medication or behavioral
therapy for smoking cessation.
The clinical parameters studied at baseline (before
smoking cessation in smokers) and at three years after
smoking cessation were all related to the effects of
smoking. These parameters included body mass index
(BMI) and serum levels of albumin (ALB), blood sugar
(BS), low-density lipoprotein cholesterol (LDL-C), total
cholesterol (TC), triglycerides (TG), and high-density
lipoprotein cholesterol (HDL-C). In addition, subjects
were evaluated and assigned GAF scores according to
DSM-IV as assessed by a psychiatrist at baseline and at
three years after smoking cessation. We also investigated
the use of antipsychotics, antiparkinsonian drugs, and
anxiolytics, namely chlorpromazine, biperiden, and di-
azepam, respectively. The required therapeutic doses of
these drugs were calculated for each patient according
to the standard equivalent conversions [18].
The study protocol was approved by the Institutional
Review Board of Seishinkai Fujisawa Hospital, and the
study was performed in accordance with the Declaration
of Helsinki. All patients provided written informed
consent after receiving detailed information regarding
the study.
R-R interval power spectral analysis
ANS activity was quantified using heart rate variability
(HRV) power spectral analysis. The technique employed
in the present investigation for detecting the three major
spectral components of HRV has been previously ap-
plied under diverse psychophysiological conditions in
basic medical science and clinical research. The validity,
reliability, and practicability of this technique have been
well documented [19–21]. HRV power spectral analysis
decomposes a series of sequential R–R intervals ob-
tained from electrocardiography (ECG) for 5 min into a
sum of sinusoidal functions of different amplitudes and
frequencies by the Fast Fourier transform algorithm
[22–27]. The spectral powers in the frequency domain
were quantified by integrating the area under the curve
for the following respective bandwidth measurements:
the low-frequency (LF; 0.03–0.15 Hz) component of
HRV representing both sympathetic and parasympa-
thetic activity; the high-frequency (HF; 0.15–0.4 Hz)
component associated almost entirely with parasympa-
thetic nerve activity; and total power (TP; 0.03–0.4 Hz)
representing overall cardiac ANS activity [24–26].
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Statistical analysis
The clinical parameters (HRV; BMI; plasma levels of
ALB, TP, BS, LDL-C, TC, TG, and HDL-C; doses of anti-
psychotics, antiparkinsonian drugs, and anxiolytic drugs;
and GAF scores) were compared between smokers and
non-smokers at baseline using Student’s unpaired t-test,
and in each group separately between baseline and at
three years after smoking cessation using Wilcoxon’s
signed-rank test. Additionally, to evaluate the effects of
smoking cessation, mean changes in the clinical parame-
ters were compared between the two groups at both
time points using the unpaired t-test. Total power, LF,
and HF data were logarithmically transformed using
Log10 to obtain normally distributed data. All statistical
analyses were performed with SPSS for Windows Ver-
sion 21.0 (IBM Corp., Armonk, NY). A p value of < 0.05
was considered statistically significant.
Results
Table 1 shows the baseline demographic and clinical pa-
rameters for all subjects. The 38 smokers comprised 7
men and 31 women, with a mean age (± standard devi-
ation) of 58.5 ± 2.3 years; the 32 non-smokers comprised
11 men and 21 women with a mean age of 54.3 ±
13.6 years. Mean duration of illness was 33.2 ± 14.5 years
and 32.7 ± 13.5 years, respectively. Compared with non-
smokers, smokers had a significantly higher HF compo-
nent and significantly higher doses of antiparkinsonian
drugs (both p < 0.05).
Table 2 shows the clinical parameters at baseline and
at three years after smoking cessation in both groups as
well as the mean changes at both time points. At three
years after smoking cessation compared with at baseline,
smokers had a significantly lower LF component and
significantly decreased doses of antipsychotics and anti-
parkinsonian drugs (both p < 0.05). Most subjects were
receiving >1 antipsychotic. BMI was significantly de-
creased and serum HDL-C was significantly increased in
both groups (both p < 0.05). Among the mean changes
in clinical parameters analyzed, only GAF score was sig-
nificantly different between smokers and non-smokers,
showing significant worsening in smokers (p < 0.05).
Discussion
Comparison of clinical parameters between smokers and
non-smokers at baseline
Our results showed that smokers had a higher HF com-
ponent than non-smokers, suggesting increased para-
sympathetic nervous system activity in smokers with
schizophrenia. This finding differs from that in healthy
subjects, in which smokers had higher sympathetic ner-
vous system activity than non-smokers [4–6], and it sup-
ports the previous findings of abnormal autonomic
nervous system activity in patients with schizophrenia
compared with healthy people [28, 29]. The required
doses of antiparkinsonian drugs at baseline were signifi-
cantly higher in smokers than in non-smokers. We sug-
gest that this finding is accounted for by higher required
doses of antipsychotic drugs in smokers compared with
non-smokers.
Clinical parameters at baseline and at three years after
smoking cessation
Our results demonstrate that long-term smoking cessa-
tion in smokers with schizophrenia was associated with
a decreased LF component, which might indicate
reduced sympathetic nervous system activity resulting
from smoking cessation. Smoking stimulates nicotinic
acetylcholine receptors in the central nervous system
and increases inflammation and oxidative stress in the
lungs, leading to increased sympathetic activity via acti-
vation of afferent neurons in the lungs [4]. Thus, our
finding suggesting that smoking cessation improved
sympathetic nervous system activity seems reasonable.
In contrast, the HF component showed no significant
Table 1 Clinical parameters between smokers and non-smokers
at baseline (before cessation of smoking)
Smokers Non-smokers P value
Number 38 32
Sex 7/31 11/21
Age (years) 57.9 ± 12.5 54.3 ± 13.6 0.241
Duration of illness 33.2 ± 14.5 32.7 ± 13.5 0.876
ln total1 4.5 ± 1.2 3.9 ± 1.2 0.071
ln LF1 3.8 ± 1.3 3.2 ± 1.4 0.163
ln HF1 3.8 ± 1.2 3.1 ± 1.3 0.016*
BMI (kg/m2) 22.7 ± 4.0 21.7 ± 4.0 0.276
ALB (g/dL) 4.0 ± 0.3 4.0 ± 0.4 0.204
BS (mg/dL) 89.7 ± 17.4 87.5 ± 15.5 0.655
LDL-C (mg/dL) 119.0 ± 33.2 108.4 ± 29.6 0.163
TC (mg/dL) 200.4 ± 42.2 183.9 ± 32.0 0.065
TG (mg/dL) 118.9 ± 91.1 86.0 ± 43.2 0.073
HDL-C (mg/dL) 60.4 ± 16.6 55.9 ± 13.2 0.222
CPZeq*2 (mg) 1229 ± 750 1162 ± 792 0.717
BPDeq*2 (mg) 2.9 ± 1.9 1.6 ± 1.6 0.003*
DZPeq*2 (mg) 10.1 ± 6.9 9.3 ± 7.4 0.653
GAF score 28.9 ± 3.1 29.2 ± 2.2 0.682
Data are presented as means ± standard deviation
*Significant difference (p < 0.05)
1Logarithmic conversion was performed
2Daily dose of antipsychotic was converted to the approximate respective
equivalent dose
LF Low Frequency, HF High frequency, BMI Body mass index, ALB Serum
albumin, BS Blood sugar, LDL-C Low-density lipoprotein cholesterol, TC Total
cholesterol, TG Triglycerides, HDL-C High-density lipoprotein cholesterol, CPZeq
Equivalent conversions of chlorpromazine, BDPeq Equivalent conversions of
biperiden, DZP Equivalent conversions of diazepam, GAF Global Assessment
of Functioning
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change after long-term smoking cessation in our patient
population, which is inconsistent with the findings of
previous studies involving healthy subjects [4, 30, 31].
Given that patients with schizophrenia have much lower
parasympathetic nervous system activity than healthy
people [28, 29], our findings seem to be influenced more
by this much lower activity than by smoking.
In this study, the required doses of antipsychotics and
antiparkinsonian drugs of the smokers were significantly
decreased after smoking cessation, but the doses of
anxiolytic drugs were not affected. Because smoking in-
creases the activity of cytochrome P450 isoenzyme 1A2
(CYP1A2) and UDP-glucuronosyltransferases (UGT),
which are responsible for drug metabolism, the metabol-
ism of antipsychotics is consequently influenced by
smoking [32]. Smoking cessation therefore results in
decreased metabolism of antipsychotics via CYP1A2 and
UGT and thus in the required dose of antipsychotics.
This is supported by the finding that, after smoking
cessation, dopamine levels were increased following a
decrease in the stimulation of nicotinic acetylcholine
receptors [33]. Our results also suggest that smoking
cessation in the long term decreased the required dose
of antiparkinsonian drugs, as a consequence of taking
lower doses of antipsychotics after smoking cessation.
In this study, smoking cessation in inpatients with
schizophrenia lowered serum HDL-C, similar to findings
in healthy individuals [7, 9]. Moreover, we found that
BMI was decreased after smoking cessation in these
inpatients, although this finding conflicts with that of a
meta-analysis reporting that people experience an in-
crease in body weight after smoking cessation because of
improved appetite [14]. This discrepancy might be
because our subjects were inpatients and received hos-
pital meals monitored by a nutritionist every day
throughout this study. In smokers with schizophrenia,
some antipsychotics cause substantial weight gain and
therefore the reduced required dose of antipsychotics
that we observed may have resulted in the decreased
BMI observed after smoking cessation. Moreover, be-
cause patients with schizophrenia usually gain weight
after smoking cessation, we educated all subjects to
avoid weight gain. Further research is needed to confirm
this speculation. Our results showed that both smokers
and non-smokers had lower HDL-C and BMI in the
long term and this may have been influenced by factors
other than smoking cessation.
Mean changes in clinical parameters at three years
among smokers and non-smokers
Our results showed a significant difference in GAF
scores between smokers and non-smokers. A previous
study revealed that smoking cessation worsened psych-
otic symptoms and increased the propensity for violence
Table 2 Changes in clinical parameters between baseline and three years later in smokers and in non-smokers
Smokers Non-smokers
n = 38 n = 32
Baseline Three years Changes p Baseline Three years Changes P Comparison
ln total1 4.5 ± 1.2 4.0 ± 1.7 −0.50 ± 1.57 0.061 3.9 ± 1.2 3.9 ± 1.4 −0.11 ± 0.95 0.681 0.218
ln LF1 3.8 ± 1.3 3.0 ± 1.8 −0.79 ± 1.73 0.049* 3.2 ± 1.4 3.2 ± 1.5 −0.09 ± 0.96 0.715 0.133
ln HF1 3.8 ± 1.2 3.4 ± 1.7 −0.44 ± 1.67 0.136 3.1 ± 1.3 3.1 ± 1.5 −0.85 ± 1.17 0.915 0.304
BMI (kg/m2) 22.7 ± 4.0 21.1 ± 3.6 −1.56 ± 3.64 0.020* 21.7 ± 4.0 20.8 ± 3.9 −0.92 ± 2.17 0.022* 0.373
ALB (g/dL) 4.0 ± 0.3 3.9 ± 0.4 −0.03 ± 0.38 0.564 4.0 ± 0.4 3.9 ± 0.4 −0.15 ± 0.46 0.076 0.240
BS (mg/dL) 89.7 ± 17.4 87.6 ± 14.6 −1.7 ± 18.6 0.568 87.5 ± 15.5 87.7 ± 14.1 0.16 ± 16.2 0.957 0.654
LDL-C (mg/dL) 119.0 ± 33.2 115.6 ± 36.2 −2.3 ± 39.0 0.717 108.4 ± 29.6 110.2 ± 27.3 1.7 ± 29.2 0.740 0.631
TC (mg/dL) 200.4 ± 42.2 190.4 ± 42.2 −10.4 ± 52.1 0.291 183.9 ± 32.0 186.3 ± 35.1 2.4 ± 27.2 0.620 0.421
TG (mg/dL) 118.9 ± 91.1 100.0 ± 48.0 −18.9 ± 93.1 0.212 86.0 ± 43.2 96.1 ± 40.8 10.2 ± 46.2 0.223 0.096
HDL-C (mg/dL) 60.4 ± 16.6 70.3 ± 18.0 9.92 ± 18.2 0.002* 55.9 ± 13.2 64.0 ± 18.9 8.1 ± 13.5 0.002* 0.635
CPZeq2 (mg) 1229 ± 750 1008 ± 646 −221 ± 576 0.031* 1162 ± 792 1075 ± 810 −86.7 ± 489 0.323 0.302
BPDeq2 (mg) 2.9 ± 1.9 2.3 ± 1.7 −0.63 ± 1.7 0.018* 1.6 ± 1.6 1.7 ± 1.7 0.15 ± 1.8 0.623 0.061
DZPeq2 (mg) 10.1 ± 6.9 8.6 ± 6.9 −1.5 ± 6.4 0.190 9.3 ± 7.4 9.1 ± 7.4 −0.12 ± 6.6 0.914 0.379
GAF score 28.9 ± 3.1 27.9 ± 4.1 −1.1 ± 3.1 0.444 29.2 ± 2.2 29.4 ± 2.1 0.15 ± 1.5 0.572 0.040*
Data are presented as means ± standard deviation
*Significant difference p < 0.05
1Logarithmic conversion was performed
2The daily dose of antipsychotics was converted to the approximate respective equivalent dose
LF Low frequency, HF High frequency, BMI Body mass index, ALB Albumin, BS Blood sugar, LDL-C Serum low-density lipoprotein cholesterol, TC Total cholesterol,
TG Triglycerides, HDL-C High-density lipoprotein cholesterol, CPZeq Equivalent conversions of chlorpromazine, BDPeq Equivalent conversions of biperiden, DZP
Equivalent conversions of diazepam, GAF Global Assessment of Functioning
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in psychiatric patients [34]. Moreover, another study re-
ported worsened GAF scores at one year after smoking
cessation [16], which is consistent with our long-term
assessment results [16]. However, we found no signifi-
cant difference in clinical factors that could explain the
difference in GAF score. Further study is needed to as-
sess the effects on psychotic symptoms in the long term.
Limitations of the study
Our study has some limitations. First, it was conducted
at a single institution and the number of subjects was
relatively small. This does not adequately reflect signifi-
cant differences in the mean changes in clinical parame-
ters between baseline and at three years among smokers
and non-smokers. Second, we did not investigate pa-
tients with schizophrenia who continued to smoke and
we did not consider the effect of sex on cholesterol
levels and ANS activity. Third, our assessment of
whether subjects smoked or not was subjective, not ob-
jective. Fourth, we did not analyze the long-term effects
of smoking cessation in the short term and whether
smoking cessation affected psychiatric symptoms such
as indicated by the Positive and Negative Syndrome
Scale (PANSS). Fifth, we did not determine the serum
concentrations of the antipsychotics and did not con-
sider the metabolism of individual antipsychotics directly
influenced by smoking, including olanzapine and halo-
peridol. Sixth, we did not take multiple testing into ac-
count because this was exploratory research. Finally,
most of our subjects were patients with schizophrenia
who had been hospitalized for a long time and these re-
sults do not therefore apply to all patients with schizo-
phrenia. Further study with a larger sample size and
other subjects such as outpatients with schizophrenia is
needed to verify our results.
Conclusions
Our findings suggest that long-term effects of smoking
cessation among inpatients with schizophrenia were not
only associated with decreased required doses of anti-
psychotics and antiparkinsonian drugs but also with im-
proved ANS activity. Further studies are needed to
clarify whether smoking cessation leads to long-term
changes in the health of patients with schizophrenia.
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